Proteasome inhibition with bortezomib (PS-341): A phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle

1. Hamilton, A.L.
2. Eder, J.P.
3. Pavlick, A.C.
4. Clark, J.W.
5. Liebes, L.
6. Garcia-Carbonero, R.
7. Chachoua, A.
8. Ryan, D.P.
9. Soma, V.
10. Farrell, K.
11. Kinchla, N.
12. Boyden, J.
13. Yee, H.
14. Zeleniuch-Jacquotte, A.
15. Wright, J.
16. Elliott, P.
17. Adams, J.
18. Muggia, F.M.